|
| |
GlioblastomaDownload PDF containing detailed information.
Recent Publications on Glioblastoma: |  |
Control of the G2/M checkpoints after exposure to low doses of ionising radiation: Implications for hyper-radiosensitivity.
Two molecularly distinct G2/M cell cycle arrests are induced after... | 21st November, 2009
| Institut Curie, Centre de Recherche, Bat. 110-112, Centre universitaire,
| DNA Repair (Amst). 2009 Nov 17.
DOI Direct Link |
Two-Step Synthesis of Multivalent Cancer-Targeting Constructs.
Selective targeting of constructs to pathological cells by conjugating one... | 21st November, 2009
| School of Biological and Health Systems Engineering, Center for
| Biomacromolecules. 2009 Nov 19.
DOI Direct Link |
CXCL12/CXCR4 promotes motility and proliferation of glioma cells.
Glioblastoma (GBM) is the most aggressive and malignant brain tumor.... | 20th November, 2009
| Centre for Neuroscience and Cell Biology and CIMAGO, University of
| Cancer Biol Ther. 2010 Jan 17;9(1).
|
Treatment of glioblastoma multiforme cells with temozolomide-BioShuttle ligated by the inverse Diels-Alder ligation chemistry.
Recurrent glioblastoma multiforme (GBM), insensitive against most... | 19th November, 2009
| German Cancer Research Center, Dept of Imaging and Radiooncology,
| Drug Des Devel Ther. 2009 Feb 6;2:289-301.
|
Induction of cytotoxicity, apoptosis and cell cycle arrest by 1-t-butyl carbamoyl, 7-methyl-indole-3-ethyl isothiocyanate (NB7M) in nervous system cancer cells.
Our group has recently developed 1-(t)butyl carbamoyl,... | 19th November, 2009
| Molecular Therapeutics Laboratory, Program in Women's Oncology, Department
| Drug Des Devel Ther. 2009 Feb 6;2:61-69.
|
→View more research publications. |
Press Releases About Glioblastoma:
|
 |
| Paloma Pharmaceuticals Presents at the AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics |
16th November, 2009 |
|
JAMAICA PLAIN, Massachusetts, November 16 /PRNewswire/ -- Paloma Pharmaceuticals, Inc. announced it will give a presentation today
at the AACR-NCI-EORTC International Conference Molecular Targets and
|
| New Study in Clinical Cancer Research Shows Therapeutic Promise of Peregrine's Bavituximab With Radiation in a Lethal Brain Cancer Model |
10th November, 2009 |
Peregrine Pharmaceuticals, Inc. |
TUSTIN, Calif., Nov. 10 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHMD) today announced that a newly published study shows that a phosphatidylserine (PS)-targeting antibody
|
| Ascenta Therapeutics Announces Presentation of Results From a Dose-Ranging Study of AT-101 With Standard Therapy in Patients With Glioblastoma Multiforme |
26th October, 2009 |
Ascenta Therapeutics, Inc. |
MALVERN, Pa., Oct. 26 /PRNewswire/ -- Ascenta Therapeutics announced today that encouraging results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral,
|
| NexGenix Pharmaceuticals Awarded Phase I Grant from the National Institute of Neurological Disorders and Stroke (NINDS) Small Business Innovation Research Program (SBIR) for the Development of Novel Small Molecule Hsp90 Therapeutics to Treat Glioma |
22nd October, 2009 |
NexGenix Pharmaceuticals Holdings, Inc. |
NEW YORK, Oct. 22 /PRNewswire/ -- NexGenix Pharmaceuticals Holdings, Inc. a privately-held biotechnology company with a portfolio of novel targeted therapies for oncology and neurodegenerative
|
| Video: Groundbreaking Project Launched to Improve Brain Cancer Treatments and Outcomes |
22nd October, 2009 |
Swedish Neuroscience Institute |
SEATTLE, Oct. 22 /PRNewswire-USNewswire/ -- A major collaborative research project focused on mapping the gene activity in brain tumors was launched today. The goal of the research, known as the Ivy
|
Companies working in the area of Glioblastoma from Bioportfolio's Biocorporate database : | |
| Company Name | |
Allos Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative drugs for improving cancer treatments. Since 1994, we have been committed to improving the health...
www.allos.com/ View full profile
| |
BSD Medical Corporation (AMEX: BSM) develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radio frequency (RF) and...
www.bsdmc.com/ View full profile
| |
EntreMed, Inc. is a clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells directly and the blood vessels that nourish them. EntreMed is...
www.entremed.com/ View full profile
| | →View more Glioblastoma related companies. |
BioPortfolio Ltd. offers e-mail and postal lists for Glioblastoma scientists - we have details of around 1290 individuals working on Glioblastoma .
This page has been viewed 1122 times
Recent Search Terms used to find this page: gbm 2009 | glioblastoma report 2009 | clinical results for brain rhabdo after gamma knife surgery for nov 2009 | clinical results for brain rhabdo after gamma knife surgery for nov 2009 | GBM Research Incorporated | gbm 2009 | glioblastoma 2009 | Enhanced MDR1 Expression and Chemoresistance of Cancer Stem Cells Derived from Glioblastoma | glioblastoma center of excellence | .
Browse BioPortfolio's InDepth service - alphabetically:
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
or by Most Publications, recently searched for, or
most viewed.
Search for Glioblastoma across BioPortfolio, or for Glioblastoma Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH.
Thumbshots from Thumbshots.org
|
